Clinical trial
Evaluation of a New Agent for Treatment of Advanced Stage Breast Cancer
NCT00313248 · Bayer, Industry · Completed
Key facts
| NCT number | NCT00313248 |
|---|---|
| Title | Evaluation of a New Agent for Treatment of Advanced Stage Breast Cancer |
| Official title | Phase 2 Study to Investigate the Efficacy and Safety of ZK-Epothilone (ZK-Epo; ZK 219477) in Patients With Metastatic Breast Cancer |
| Lead sponsor | Bayer, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Breast Neoplasm |
| Intervention type | Drug |
| Interventions | Sagopilone (ZK 219477) |
| Enrollment | 65 |
| Start date | Apr 1, 2006 |
| Primary completion | Oct 1, 2008 |
| Completion | Nov 1, 2008 |
| First posted | Apr 12, 2006 |
| Last update posted | Dec 10, 2015 |
| Countries | Canada, United States |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: